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INTRODUCTION
Numbers of individuals infected with Human Im-
munodeficiency Virus (HIV) are increasing in Japan
(1, 2). The majority of them are Men who have sex
with men (MSM), who infect with HIV through sex-
ual intercourse (1, 3). A part of MSM with high sex-
ual activity takes multiple drugs as ‘Sex drug’ at
their sexual intercourse, and the sexual behavior
using the drugs is correlated with the high risk of
HIV infection in Japanese MSM as well (4).
Among HIV- infected Japanese drug users, in
addition to a casual snort of amyl nitrate, metham-
phetamine, 3, 4-methylenedioxy- methamphetamine
(MDMA ; called as ‘Ecstasy’) and 5-methoxy-N, N-
diisopropyltryptamine (5-MeO-DIPT ; amphetamine
analog, ‘Foxy’) are preferentially ingested, and these
had been reported to induce the rhabdomyolysis
(5-7). And several reports describe the interaction
between these drugs and anti-HIV reagents as the
elevated drug concentration in plasma (8-10). Nowa-
days, the drugs are taken without the concern about
the interaction or the toxicity, and some drug users
are carried to emergency hospitals due to the drug-
induced troubles. However, the actual drug-induced
trouble among Japanese HIV-infected drug users
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had not yet been discussed enough.
In this report, we describe three cases with HIV
infection ; a case developed severe neuroleptic ma-
lignant syndrome (NMS) after taking 5-MeO-DIPT,
a case with persistent convulsion due to multiple
drugs intake and a case with rhabdomyolysis due
to the non-subjective methamphetamine intake.
Through these cases, we raise and discuss the prob-




A 28-year-old MSM was a 5-MeO-DIPT user for
two years. He took duplicate dose of 5-MeO-DIPT
rectally concomitant with sildenafil citrate (Viagra)
orally for homosexual intercourse. Fifteen hours
after the drug intake, he was transferred with un-
consciousness to the department of critical care
medicine of our hospital. His consciousness level
was low at Glasgow Coma Scale E1V1M4 and Japan
Coma Scale 200. His body temperature was over
40, blood pressure 140/ 87 mmHg and pulse rate
107/ min. His respiratory sound was normal vesicu-
lar. He was positive in HIV screening test. His CD4+
count was 220/μl with a viral load of 1,500 copies/
ml. Laboratory data was as follows ; CPK 122,700
IU/L (normal : 62-287), CPK-MB 1,560 IU/L (0-
16), Myoglobin 700 ng /ml (0-76), AST 1381 IU/L
(13-33), ALT 515 IU/L (8-42), LDH 5040 IU/L
(119-229), T-bil 1.0 mg/dl (0.3-1.2), Glucose 113
mg/dl (69-104), BUN 45 mg/dl (8-22), Cre 4.75
mg/dl (0.6-1.1), WBC 15,300/μl (4,000-8,000), Hb
13.7 g/dl (14-17), Platelet 113,000 /μl (130,000-
350,000). He was negative in HBs-antigen, HCV-
antibody, Rapid plasma reagin test (RPR) and Tre-
ponema pallidum hemagglutination test (TPHA).
Blood gas analysis (with oxygen mask ; O2 10L/
min) was as follows ; pH 7.23 (Normal : 7.35-7.45),
PaO2 341.0 torr (over 75), ABE -10.2mmol/L ((-2.2)
-1.2), PaCO2 41.9 torr (35-45) and HCO3- 16.8 mmol/
L (23-28). Alcohol or other drugs were not detected
in his blood screening.
Drip infusion therapy for the high level of Cre
didn’t increase his urination because his acute re-
nal failure had already progressed. Immediately,
hemo-dialysis with continuous hemodia filtration
(CHDF) started. Even three days later, his high
fever over 38.2, elevated CPK (181,200 IU/L)
were not yet improved and myotonia with muscle
rigidity appeared. Diagnosis of NMS was made by
the diagnostic criteria (11, 12). Then dantrolene
(1mg/kg) treatment was administrated. In the next
day, his CPK began to decrease and reached 2,733
IU/L within a week. His consciousness recovered
after the forth day. His clinical presentations and
laboratory data improved within two months com-
pletely. However, he complained a mild disturbance
in memory, speech and finger movement. Then, his
blood brain scintigraphy showed a decreased blood
flow in whole cerebrum although his brain mag-
netic resonance imaging (MRI) showed no abnor-
mal findings. The Japanese version of the neurobe-
havioral cognitive status examination showed very
slight word dumbness and decrease of ability in
both attention and concentration although all items
of cognitive status profile were within normal range.
He discharged from hospital two months later.
Passing three years of this episode, his HIV in-
fection had been controlled well. However, his neu-
rological disorders in memory, speech and finger
movement remained.
Case 2
A 28-year-old MSM had been followed up at our
hospital under highly active anti-retroviral therapy
(HAART) with Tenofovir (TDF) /Lamivudine (3
TC) and Atazanavir (ATV). He took a 5-MeO-DIPT,
MDMA, and amyl nitrite. The next morning he
was transferred to our hospital with pain on mus-
cle and knee joint, convulsions and consciousness
loss. At arrival, he showed multiple tonic-clonic con-
vulsions in every 15 minutes. His blood pressure
was 100/50 mmHg, respiratory rate was 18 /min
regularly, and his body temperature was 35.9.
His CD4+ count was 901 /μl with undetectable
viral load of under 50 copies/ml. His laboratory data
was as follows ; AST 25 IU/L, ALT 24 IU/L, LDH
159 IU/L, T-bil 1.1 mg/dl, CPK 240 IU/L, BUN 10
mg/dl, Cre 0.84 mg/dl, WBC 5,700/μl, Hb 15.0 g/
dl, Plt 250,000 /μl, Na 140 mEq/l, K 3.9 mEq/l, Cl
108 mEq/l, Ca 8.7mg/dl. His brain computed to-
mography (CT) and MRI did not show any abnor-
mal findings.
However, a treatment with diazepam and pheny-
toin for his tonic-clonic convulsion was not effective
and the convulsion was observed in every 8 hours
with following 30 to 90 second apnea. His respira-
tory was controlled under intra-tracheal intubations
with anti-convulsion therapy via propofol 3 mg/kg/
hr and phenytoin 500-650 mg/day. His electric en-
cephalography (EEG) showed no specific disorder
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in resting time while it showed three Hz slow wave
at bilateral frontal and temporal lobes in convuls-
ing time. His brain blood scintigraphy pointed out a
decreased brain blood flow in the whole cerebrum.
He was a multiple-drug user as follows ; Mari-
juana and cocaine for more than 10 years, amyl ni-
trate more than 7 years, MDMA more than 7 months
and crystal methamphetamine for one month. How-
ever, he had concealed the history of multiple-drug
addiction from our medical staff. He had no epi-
sode of convulsions before this administration.
Then he was diagnosed as epilepsy, drug-induced
mental disorder and poly-drug dependence. Two
months later, he could discharge the hospital un-
der HAART administration in tight control of the
convulsion with sodium valproate. However, he in-
curred convulsions by taking the multiple drugs
again. His convulsion was barely controlled by so-
dium valproate for two weeks and he quitted drugs.
Four month later, he still showed multiple convul-
sions regardless of drug use. Instead of the prophy-
laxis with sodium valproate, his convulsion remains
a major problem.
Case 3
A 32-year-old MSM had been treated with TDF /
Emtricitabin (FTC) and ATV boosted by Ritonavir
(RTV). He had a homosexual intercourse with un-
known beverage at five days ago. The next day, he
visited outpatient ward due to dark-red urine, gen-
eral fatigue, muscular pain and appetite loss. His
CD4+ count was 823 /μl and HIV-RNA was under 50
copies/ml. His laboratory data were as follows ; AST
44 IU/L, ALT 27 IU/L, LDH 239 IU/L, T-bil 7.3
mg/dl, Glucose 122 mg/dl, CPK 713 IU/L, BUN 12
mg/dl, Cre 0.68 mg/dl, haptoglobin 201mg/dl (19-
170), WBC 4,900/μl, Hb 13.6 mg/dl, Plt 200,000 /
μl, Na 142 mEq/l, K 4.0 mEq/l, Cl 108 mEq/l. Myo-
globin was not measured. Drug screening test of
urine showed positive reaction to amphetamine
whereas the other drug reaction was not pointed
out. He did not have any episodes of the fall or the
injury. Drip infusion therapy for elevated CPK was
performed for four days. Then his CPK was nor-
malized up to 205 IU/L and his symptoms were im-
proved within three days as well. He was an amyl
nitrate, 5-MeO-DIPT and 4-methoxy-N-methyl-N-
isopropyltryptamine (4-MeO-MIPT) user occasion-
ally at sexual intercourse for these ten years. How-
ever, this was his first amphetamine intake and was
his first experience of physical disorders by drugs
as well.
DISCUSSION
In this report, we described three cases with vari-
ous kinds of problems, which are related to drug
users with HIV infection. The first problem is found
in Case 1 as the unknown physical toxicity of 5-MeO-
DIPT which is a hallucinogenic reagent that modu-
lates neuron’s activity in the forebrain like MDMA
(13-16). Pharmacologically, 5-MeO-DIPT is mainly
metabolized in Cytochrome P450 2D6 (CYP2D6)
(17). However, the genetic polymorphism analysis
of CYP2D6 revealed many variations including the
5-10% of poor metabolizers (18, 19). On the other
hand, the detection method of 5-MeO-DIPT is still
in an investigational stage (20, 21). In such back-
ground, we discuss the reason why Case 1 showed
acute renal failure due to rhabdomyolysis and even-
tually developed NMS which is severer than the
cases described in the previous reports (7, 22). Cer-
tainly, the frequent drug use increases the oppor-
tunities of accident on a poor metabolizer by the
drug. Moreover, it is uncertain whether he is a poor
metabolizer genetically. However, it is impossible
to understand that NMS may happen by only the
double doses of 5-MeO-DIPT even if Case 1 is a
poor metabolizer. Then we consider additional fac-
tors with HIV infection. Even if the HIV-infected
individuals do not need HAART yet, they hold higher
risk of physical troubles or allergic reaction than
non-infected individuals do (23, 24). These reports
indicate that HIV certainly induces physical insta-
bility although the mechanism is not yet clear. The
patient of Case 1 actually developed severer fatal
NMS than the cases that had ever reported and he
had complained the mental/ neurological disorder
for followed three years. Thus, we should always
consider that drug may cause unknown physical
toxicity on HIV infected drug users.
The second problem is the unknown neurologi-
cal toxicity of the drugs. Case 2 caused intractable
convulsion after multiple drug use including 5-MeO-
DIPT, MDMA and amyl nitrate. However, intracta-
ble convulsion after 5-MeO-DIPT use had not been
reported. Each of 5-MeO-DIPT and MDMA were
reported to show the overlapping toxicity on neu-
rons (25, 26). Thus, multiple drugs use might cause
the unknown neurological toxicity. We consider that
Case 2 might potentially possess the genetic/ im-
munologic factors to cause neurological toxicity like
Case 1. It should be considered that multiple drug
use by Case 2 increased a risk of organ damage
more, and it resulted in persistent intractable con-
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vulsion, actually.
The third problem is an unexpected non-subjective
drug intake and drug interaction under HAART ad-
ministration. Case 3 caused rhabdomyolysis by tak-
ing methamphetamine contained in beverage with-
out his intent. Methamphetamine intake is imper-
missible especially for HIV-infected individuals on
HAART. Case 3 took HAART with TDF/FTC and
ATV boosted by RTV at this episode. RTV, one of
the HIV-Protease Inhibitors (PIs), can elevate plasma
concentration of other PIs through the inhibitory
effect on a metabolism at cytochrome P450 3A4
(CYP3A4) (27, 28). However, methamphetamine,
5-MeO-DIPT and MDMA should be alternatively
metabolized by CYP3A4 although they are metabo-
lized mainly by P450 2D6 (CYP2D6) (17, 19). On
the other hand, RTV is a potent inhibitor of cyto-
chrome CYP2D6 as well (29). Thus, the concomi-
tant intake of drug on RTV would elevate plasma
concentration of the drugs over the toxicity limit.
A previous paper reported that RTV increase the
MDMA concentration up to 8.8 fold and metham-
phetamine up to 2 to 3 fold in blood (8). As a mat-
ter of fact, the fatal cases by MDMA and metham-
phetamine with RTV are also reported (9, 10).
These days, many of HIV individuals on HAART
use RTV as a booster of PIs. Though it is not clear
how RTV effected on the onset of rhabdomyolysis
in Case 3, non-subjective drug intake out of the con-
sideration of RTV including HAART is impermissi-
ble.
Thus, we strongly insist that a dangerous behav-
ior concerning the drug use should be monitored
in patient health care because the interaction by
RTV is not well known in general.
In this report, we described several problems
on HIV-infected drug users. The problem of drug
users with HIV infection had not yet discussed in-
tensively in Japan. Even though HIV infection was
controllable, the problems of drug use remained in
these cases certainly. Through these cases in our
report, we wish that the underlying problems were
recognized, discussed and reflected on medication
and education for the HIV patient care.
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